

August 25, 2026

The Manager- Listing
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai – 400 001

The Manager- Listing
National Stock Exchange of India Limited
Exchange Plaza,
Bandra – Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Update

This is pursuant to Regulation 30(7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our communication dated July 28, 2026, in connection with the demand notice dated July 27, 2026 ('Demand Notice') issued by the National Pharmaceutical Pricing Authority ('NPPA') for alleged overcharging under the Drugs (Prices Control) Order, 2013 with respect to Betaloc-50 (Metoprolol 50 mg tablets).

We hereby inform that, the Hon'ble High Court of Delhi, vide its order dated August 24, 2026, has stayed the operation of the aforesaid Demand Notice until the next date of hearing i.e. February 10, 2027, subject to the Company depositing 15% of the amount mentioned in the Demand Notice with the Registrar General of the Court.

Further, please find the details as required under the SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 attached herewith as **Annexure – A**.

Kindly take the above information on record.

Thanking You,
For AstraZeneca Pharma India Limited

Tanya Sanish
Company Secretary & Compliance Officer

Annexure – A

Sl. No.	Particulars	Details
1.	Name of the authority	Hon'ble High Court of Delhi
2.	Nature and details of the action(s)	Order dated August 24, 2026 passed in W.P.(C) 12314/2026 & CM APPL. 57158-59/2026, titled AstraZeneca Pharma India Limited v. National Pharmaceutical Pricing Authority, Department of Pharmaceuticals & Anr., the NPPA demand notice dated July 27, 2026.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	August 24, 2026
4.	Details of the violation(s)/contravention(s) committed or alleged to be committed	NPPA has alleged that AstraZeneca Pharma India Ltd. sold/marketed Betaloc-50 (Metoprolol 50 mg tablets) at an MRP higher than the ceiling price notified under DPCO, 2013, and has not implemented the revised ceiling price on stocks available in the market from the notifications i.e. Notification S.O. 644(E) dated 02.03.2016 and Notification S.O. 1352(E) dated 02.06.2016 in respect of Betaloc-50 tablets. This has allegedly resulted in overcharging during the period of June to July 2016, for which NPPA has demanded recovery of the overcharged amount along with applicable interest The Company challenged the Demand Notice before the Hon'ble High Court of Delhi. Vide order dated August 24, 2026, the Hon'ble High Court of Delhi has stayed the operation of the Demand Notice until the next date of hearing i.e. February 10, 2027, subject to the Company depositing 15% of the amount mentioned in the Demand Notice with the Registrar General,

		Delhi High Court. The Company is taking necessary steps in this connection.
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	15% of the amount mentioned in the Demand Notice.